Literature DB >> 15526358

Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance.

Zhi-Jun Zeng1, Lian-Yue Yang, Xiang Ding, Wei Wang.   

Abstract

AIM: To investigate the expression of cysteine-rich61 (Cyr61), connective tissue growth factor (CTGF) and nephroblastoma overexpressed gene (Nov) in hepatocellular carcinoma (HCC), and to evaluate the relationship between Cyr61, CTGF and Nov genes expression with invasion and metastasis of HCC.
METHODS: Thirty-one HCC specimens were divided into small hepatocellular carcinoma (SHCC), nodular hepatocellular carcinoma (NHCC), solitary large hepatocellular carcinoma (SLHCC) according to their diameter and number of nodes. Reverse transcription polymerse chain reaction (RT-PCR) was used to detect the mRNA expression levels of Cyr61, CTGF and Nov genes in 31 resected specimens of hepatocellular carcinoma and para-cancerous normal liver tissues semi-quantitatively and the relation between their expression levels and clinical pathological parameters were compared.
RESULTS: The expressions of Cyr61 and CTGF mRNA in carcinoma tissues were significantly higher than those in para-cancerous normal liver tissues (P<0.01). The expressions of Cyr61 and CTGF mRNA in HCC with venous invasion were higher than those in HCC without venous invasion. CTGF expression in HCC Edmondson's grade III-IV was significantly higher than that in HCC Edmondson's grade I-II (P = 0.022). There was no obvious correlation between Nov mRNA and clinical-pathological features. Compared to NHCC, SLHCC had better cell differentiation, easier capsule formation, less microscopic venous invasion, milder liver cirrhosis. The expressions of Cyr61 and CTGF mRNA in NHCC were significantly higher than those in SLHCC and SHCC.
CONCLUSION: Cyr61 and CTGF genes may play an important role in hepatocellular carcinogenesis and correlate with recurrence and metastasis of hepatocellular carcinoma. SLHCC has better biological behaviors than NHCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526358      PMCID: PMC4576220          DOI: 10.3748/wjg.v10.i23.3414

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  The modular architecture of a new family of growth regulators related to connective tissue growth factor.

Authors:  P Bork
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

4.  Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor.

Authors:  D R Brigstock; C L Steffen; G Y Kim; R K Vegunta; J R Diehl; P A Harding
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

5.  CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.

Authors:  A M Babic; M L Kireeva; T V Kolesnikova; L F Lau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  The pig as a model for excisional skin wound healing: characterization of the molecular and cellular biology, and bacteriology of the healing process.

Authors:  J F Wang; M E Olson; C R Reno; J B Wright; D A Hart
Journal:  Comp Med       Date:  2001-08       Impact factor: 0.982

7.  Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells.

Authors:  A Astolfi; C De Giovanni; L Landuzzi; G Nicoletti; C Ricci; S Croci; L Scopece; P Nanni; P L Lollini
Journal:  Gene       Date:  2001-08-22       Impact factor: 3.688

8.  Histopathologic differentiation of the main nodule determines outcome after hepatic resection for synchronous multicentric hepatocellular carcinomas.

Authors:  Shun-ichi Ariizumi; Ken Takasaki; Masakazu Yamamoto; Takehito Ohtsubo; Hideo Katsuragawa; Satoshi Katagiri
Journal:  Hepatogastroenterology       Date:  2004 Mar-Apr

9.  CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.

Authors:  Cristiane G Lin; Shr-Jeng Leu; Ningyu Chen; Christopher M Tebeau; Shao-Xia Lin; Cho-Yau Yeung; Lester F Lau
Journal:  J Biol Chem       Date:  2003-04-13       Impact factor: 5.157

10.  Localization of connective tissue growth factor during the period of embryo implantation in the mouse.

Authors:  G A Surveyor; A K Wilson; D R Brigstock
Journal:  Biol Reprod       Date:  1998-11       Impact factor: 4.285

View more
  22 in total

1.  Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice.

Authors:  Ayako Ohara; Yasuhiko Takahashi; Miwa Kondo; Yu Okuda; Shuji Takeda; Masahiko Kushida; Kentaro Kobayashi; Kayo Sumida; Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2017-08-24       Impact factor: 3.524

2.  CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC.

Authors:  Erawan Borkham-Kamphorst; Claudia R van Roeyen; Eddy Van de Leur; Jürgen Floege; Ralf Weiskirchen
Journal:  J Cell Commun Signal       Date:  2011-07-05       Impact factor: 5.782

3.  CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Authors:  Albrecht Neesse; Kristopher K Frese; Tashinga E Bapiro; Tomoaki Nakagawa; Mark D Sternlicht; Todd W Seeley; Christian Pilarsky; Duncan I Jodrell; Suzanne M Spong; David A Tuveson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

Review 4.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis.

Authors:  Tsu-Yao Cheng; Ming-Shiang Wu; Kuo-Tai Hua; Min-Liang Kuo; Ming-Tsan Lin
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth.

Authors:  Ming Xiu; Ya-Hui Liu; David R Brigstock; Fang-Hui He; Rui-Juan Zhang; Run-Ping Gao
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 6.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

7.  The 5' untranslated regions (UTRs) of CCN1, CCN2, and CCN4 exhibit cryptic promoter activity.

Authors:  Bau-Lin Huang; Lisa M Dornbach; Karen M Lyons
Journal:  J Cell Commun Signal       Date:  2007-03-28       Impact factor: 5.782

8.  CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition.

Authors:  Takashi Nishida; Seiji Kondo; Azusa Maeda; Satoshi Kubota; Karen M Lyons; Masaharu Takigawa
Journal:  Bone       Date:  2008-09-13       Impact factor: 4.398

9.  LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor.

Authors:  Lihua Ying; Agatha Lau; Cristina M Alvira; Robert West; Gordon M Cann; Bin Zhou; Caroline Kinnear; Eric Jan; Peter Sarnow; Matt Van de Rijn; Marlene Rabinovitch
Journal:  J Cell Sci       Date:  2009-04-14       Impact factor: 5.285

10.  Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer.

Authors:  Lu-Ying Liu; Yan-Chun Han; Shu-Hua Wu; Zeng-Hua Lv
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.